What You Should Know:
– Natera, Inc., a global leader in cell-free DNA and precision medicine, and Flatiron Health, a healthtech company focused on oncology solutions, have announced the integration of Natera’s oncology testing portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.
– The two-way integration allows for seamless electronic ordering and results delivery of Natera’s oncology tests, including the molecular residual disease (MRD) test Signatera
, directly within the clinical workflow of thousands of U.S. cancer care providers. The goal of the partnership is to equip providers with smart, connected tools that enhance care delivery without adding complexity.
Accelerating Insights for Confident Treatment Decisions
The integration is designed to enhance efficiency and accelerate access to crucial molecular insights.
- Unified Ordering: Oncologists now have a single, unified ordering experience for all of Natera’s oncology offerings built directly into the EMR system.
- Timely Results: Once processed, test results are returned electronically to the ordering provider within the OncoEMR interface, ensuring timely access to actionable insights.
Expanding Access to MRD Testing Across Community Oncology
The integration creates a seamless experience for over 4,500 providers across 1,000 community-based care locations nationwide that use OncoEMR. This enhanced accessibility makes it easier to incorporate advanced molecular residual disease (MRD) testing and monitoring into routine cancer care.
Minetta Liu, M.D., chief medical officer of oncology at Natera, emphasized the operational benefit: “This integration was designed with their daily workflows in mind—reducing administrative steps and accelerating access to molecular insights that can be used to guide confident treatment decisions.”
